A Potential Breakthrough for Multiple Sclerosis Novartis has recently shared promising clinical trial data regarding remibrutinib, an oral Bruton’s tyrosine kinase (BTK) inhibitor currently being studied for the treatment of relapsing multiple sclerosis (RMS). The latest findings highlight the drug’s potential to significantly improve outcomes for patients living with this challenging condition. Significant Reduction in…